Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Nuvustotug, an antibody targeting OX40.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Mavrostobart, an antibody targeting CD73.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ingitamig, an antibody targeting BCMA × KLRK1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Emunkitug, an antibody targeting TNFRSF1B.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Clesitamig, an antibody targeting DLL3 × CD3&TNFRSF9.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Cizutamig, an antibody targeting BCMA × CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Atenastobart, an antibody targeting 4-1BB.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Sirtratumab, an antibody targeting SLITRK6.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Encelimab, an antibody targeting LAG-3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Demupitamab, an antibody targeting EGFR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Runimotamab, an antibody targeting HER2 × CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ispectamab, an antibody targeting BCMA.